Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pravastatin sodium Clear all
Not listed Not applicable Interventional

Longitudinal Study of Multi-Analyte Profile for Dyslipidemia

NCT01441908
View directory record Official record
Conditions
Dyslipidemia
Interventions
Pravastatin
Drug
Lead sponsor
MaiHealth Inc
Other
Eligibility
30 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2012 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

NCT00017758
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Lipodystrophy
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2006 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

NCT00166036
View directory record Official record
Conditions
Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
Interventions
Atorvastatin, Pravastatin
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2014 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome

NCT01845428
View directory record Official record
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Pravastatin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 17, 2026, 2:30 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01342887
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
Interventions
cyclosporine, pravastatin sodium, mitoxantrone hydrochloride, etoposide, bone marrow aspiration
Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Pravastatin for Prevention of Preeclampsia

NCT01717586
View directory record Official record
Conditions
Preeclampsia
Interventions
Pravastatin, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
3
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index

NCT05524246
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant (HSCT), Endothelial Injury
Interventions
Pravastatin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects

NCT01301066
View directory record Official record
Conditions
Dyslipidemia
Interventions
Pitavastatin, Pravastatin
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
35
States / cities
Phoenix, Arizona • Beverly Hills, California • Costa Mesa, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

NCT00245388
View directory record Official record
Conditions
Dyslipidemia
Interventions
Muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
53
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Irvine, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT04284657
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Pravastatin, sodium citrate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT00456365
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
pravastatin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 22 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males

NCT02547402
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
CXA-10, pravastatin, Vytorin® (combination of simvastatin and ezetimibe)
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
19 Years to 30 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Not applicable Interventional Results available

Effect of Succinylcholine on Patients Using Statins

NCT00986583
View directory record Official record
Conditions
Pain
Interventions
Succinylcholine
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Sep 17, 2026, 2:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

NCT03947385
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Interventions
IDE196, Binimetinib, Crizotinib
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

NCT00697203
View directory record Official record
Conditions
Dyslipidemia
Interventions
Placebo, Pravastatin, Dalcetrapib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
33
States / cities
Mobile, Alabama • Scottsdale, Arizona • Newark, Delaware + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV

NCT02841774
View directory record Official record
Conditions
HIV Infection, Coronary Heart Disease
Interventions
Pravastatin, Rosuvastatin
Drug
Lead sponsor
Matthew Feinstein
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

NCT00127218
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
any statin, niacin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 17, 2026, 2:30 PM EDT
Terminated Phase 2 Interventional Results available

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

NCT03219372
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cirrhoses
Interventions
Pravastatin Pill, Placebo Oral Tablet
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 17, 2026, 2:30 PM EDT
Not listed Not applicable Interventional

Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study

NCT00599625
View directory record Official record
Conditions
Crohn's Disease
Interventions
Pravastatin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Sep 17, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

NCT06912763
View directory record Official record
Conditions
Fibrosis Syndrome, Lymphedema, Head &Amp; Neck Cancer, Fibrosis
Interventions
Pravastatin (drug), Pentoxifylline, ketoprofen, Pirfenidoneone, Standard of Care (SOC), tocopherol
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 4 Interventional

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Pravastatin for at Least 4 Weeks.

NCT00755352
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
pravastatin tablets and Welchol tablets, pravastatin tablets and Welchol placebo tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
15
States / cities
Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

NCT03131973
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
BMS-986195, Methotrexate, Leucovorin, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, Pravastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 17, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

NCT00107523
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, idarubicin, pravastatin
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 17, 2026, 2:30 PM EDT